MarketCap
Facebook
X
Telegram
Lumos Pharma Total Non Current Liabilities | LUMO
Annual Total Non Current Liabilities Lumos Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6 M | 6.2 M | 6 M | 191 K | 6.95 M | 7.11 M | 7.38 M | 7.93 M | 9.26 M | 8.35 M | 8.58 M | 942 K | 7.09 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.26 M | 191 K | 6.31 M |
Quarterly Total Non Current Liabilities Lumos Pharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 6.19 M | 6 M | 6.02 M | 6.08 M | 6.13 M | 6.2 M | 6.29 M | 6.37 M | 6.11 M | 6 M | 10.7 M | 13.2 M | 14.6 M | 191 K | 6.22 M | 13.5 M | 13.4 M | 6.95 M | 6.99 M | 7.03 M | 7.06 M | 7.11 M | 7.16 M | 7.22 M | 7.3 M | 7.38 M | 7.42 M | 7.56 M | 7.8 M | 7.93 M | 8.19 M | 8.46 M | 8.73 M | 9.26 M | 8.25 M | 8.22 M | 8.29 M | 8.35 M | 8.42 M | 8.49 M | 8.52 M | 8.58 M | 8.64 M | 8.29 M | 8.34 M | 942 K | 988 K | 942 K | 942 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 M | 191 K | 7.32 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
81.7 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
326 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
13.2 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
5.95 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
341 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
302 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
40.3 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
196 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
99.5 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
31.9 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
23.1 M | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
4.31 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
272 K | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
64.5 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
30.5 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
9.54 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
59.9 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
2.34 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
6.68 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
541 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
12.2 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
20 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
93.1 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
940 K | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
22.2 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
33.6 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
150 K | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
73 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
148 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
13.1 M | - | - | $ 229 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
14.9 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
25.2 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
999 K | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
4.94 K | - | 70.13 % | $ 4.12 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
752 K | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
368 K | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
35.4 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
41.6 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
6.35 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
91 K | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
18.7 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
50.9 M | - | 1.02 % | $ 90.8 M | Britain |